Integration of chemotherapy in the curative treatment of locally advanced head and neck cancer

References

• Forastiere A, Koch W, Trotti A, Sidransky D. Medical progress: head and neck cancer. NEngif Merl 345 (26), 1890–1900 (2001).
   Google Scholar
• •Recent review on head and neck cancer.
   Google Scholar
• Vokes E, Kies M, Haraf D et al Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. j Clin. Onco1.18, 1652–1661 (2000).
   Google Scholar
• Robbins KT, Kumar P, Regine WF et al Efficacy of targeted supradose cisplatin and concomitant radiation therapy for advanced head and neck cancer: the Memphis experience. Int. J. Racliat. Oncol Biol. Phys. 38(2), 263–271 (1997).
   Google Scholar
• Adelstein DJ. Induction chemotherapy in head and neck cancer. Hematol °nevi Gun. North A117.13(4), 689–698 (1999).
   Google Scholar
• Harari P. Why has induction chemotherapy for advanced head and neck cancer become a United States community standard of practice?' Gun. Oncol 15,2050–2055 (1997).
   Google Scholar
• Rooney M, Kish J, Jacobs J et al Improved complete response rate and survival in advanced head and neck cancer. Cancer 55, 1123–1128 (1985).
   PubMed Web of Science ®Google Scholar
• Pignon J, Bourhis J, Domenge C, \ Designe L, Group M-NC. Chemotherapy added to locoregional treatment for head and neck squamous-cell cancer: three meta-analyses of updated individual data. Lancet 355,949–955(2000).
   PubMed Web of Science ®Google Scholar
• ••Important meta-analysis indicating thesuperiority of chemoradiotherapy.
   Google Scholar
• Monnerat C, Faivre S, Temam S, Bourhis J, Raymond E. End points for new agents in induction chemotherapy for locally advanced head and neck cancers. Ann. Onco1.13, 995–1006 (2002).
   Google Scholar
• Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl. I Merl 324, 1685–1689 (1991).
   Google Scholar
• •Landmark study of organ preservation.
   Google Scholar
• Lefebvre J, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer Phase III trial. J. Natl Cancer Inst. 88(13), 890–898 (1996).
   PubMed Web of Science ®Google Scholar
• Domenge C, Hill C, Lefebvre J et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. BE J. Cancer 83(12), 1594–1598 (2000).
   Google Scholar
• Paccagnella A, Orlando A, Marchiori C et al. Phase III trial of initial chemotherapy in Stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del collo J. Natl Cancer Inst. 86,265–272 (1994).
   Google Scholar
• Colevas A. Docetaxel in squamous cell carcinoma of the head and neck. Cancer Invest.17, 62–63 (1998).
   Google Scholar
• Catimel G, Verwij J, Hanauske A. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann. Oncol 5,553–537 (1994).
   Google Scholar
• Colevas A, Busse P, Norris C et al Induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL5) for squamous cell carcinoma of the head and neck: a Phase VII trial. j Clin. awl 16,1331–1339 (1998).
   Google Scholar
• Colevas A, Norris C, Tishler R et al A Phase II trial of TPFL (docetaxel, cisplatin, 5-fluorouracil, leucovorin) as induction for squamous cell carcinoma of the head and neck (SCCHN).j Clin. °nevi 17(11), 3503–3511 (1999).
   Google Scholar
• Colevas AD, Norris CM, Tishler RB et al. Phase VII trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN) Am. I Clin. Oncol 25 (2), 153–159 (2002).
   Google Scholar
• Posner M, Glisson B, Frenette G et al. A multi-center Phase I—II trial of docetaxel, cisplatinum and 5-fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck.j Clin. Oncol 19,1096–1104 (2001).
   Google Scholar
• Haddad R, Norris C, Sulivan C et al. Docetaxel, cisplatin and 5-fluorouracil based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana—Farber Cancer Institute experience. Cancer 97 (2), 412–418 (2003) .
   Google Scholar
• •Experience with docetaxel/cisplatin/5-FU (TPF) chemotherapy from the Dana—Farber Cancer Institute (MA, USA).
   Google Scholar
• Calais G, Alfonsi M, Bardet E et al Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced stage oropharynx carcinoma. J Natl Cancer Inst. 91,2081–2086 (1999).
   PubMed Web of Science ®Google Scholar
• •Important chemoradiotherapy study.
   Google Scholar
• Sutharalingum M, Haas M, Conley B et al The use of carboplatinum and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. Int. J Rad. Biol. Oncol Phys. 47,49–56 (2000).
   Google Scholar
• Brizel D, Albers M, Fisher S et al Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engif Merl 338,1798–1804 (1998).
   PubMed Web of Science ®Google Scholar
• Staar S, Rudat V, Stuetzer H et al Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy — results of a multicentric randomized German trial in advanced head and neck cancer. Int. J Rad. Oncol Phys. 50(5), 1161–1171 (2001).
   Google Scholar
• Fu K, Pajak T, Troth A et al A Radiation Therapy Oncology Group (RTOG) Phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int. J Rad. Biol. Oncol Phys. 48,7-16 (2000).
   Google Scholar
• •Randomized study of different radiation regimens.
   Google Scholar
• Adelstein D, Li Y, Adams G et al. An Intergroup Phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. j Clin. Oncol 21, 92–98 (2003).
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Berkey B, Maor M et al Phase III trial to preserve the larynx: induction chemotherapy and radiotherapy versus concomitant chemoradiotherapy versus radiotherapy alone, Intergroup Trial R91-11. Proc. Am. Soc. Clin. Oncol 20(1) (2001) (Abstract 4).
   Google Scholar
• •Randomized study for organ preservation.
   Google Scholar
• Machtay M, Rosenthal DI, Hershock D et al Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: a University of Pennsylvania Phase II triaLj Clin. 017C0i 20(19), 3964–3971 (2002).
   Google Scholar
• •Sequential chemoradiotherapy from Unversity of Pennsylvannia (PA, USA).
   Google Scholar
• Vokes EE, Stenson K, Rosen FR et al Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin. °nevi 21(2), 320–326 (2003).
   Google Scholar
• •Sequential chemoradiotherapy from the University of Chicago (IL, USA).
   Google Scholar
• Gray J, Meluch A, Greco F et al Induction paclitaxelicarboplatin/5-FU followed by concurrent radiotherapy and weekly paclitaxelicarboplatin for patients with locally advanced head and neck cancer (HNC): a Minnie Pearl Cancer Research Network Trial. Proc. Am. Soc. Clin. 017C0i 20(1), (2001) (Abstract 226).
   Google Scholar
• Urba S, Moon J, LeBlanc M et al Induction chemotherapy followed by chemoradiation for organ preservation in patients (pts) with advanced resectable cancer of the base of tongue (BOT) and hypopharynx (HE') : a Southwest Oncology Group trial. Proc. Am Soc. Clin. Oncol 21 (1), (2002) (Abtract 230).
   Google Scholar
• Posner M, Colevas A, Tishler R. The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck. Semin. Oncol 27(Suppl. G), 13–24 (2000).
   Google Scholar
• Cognetti F, Pinnaro P, Ruggeri EM et al Prognostic factors for chemotherapy response and survival using combination chemotherapy as initial treatment of advanced head and neck squamous cell cancer. 1 Clin. Oncol 7(7), 829–837 (1989).
   Google Scholar